聚焦超声和哈西奈德治疗外阴白色病变的全国多中心随机对照研究

注册号:

Registration number:

ChiCTR-TRC-09000434 

最近更新日期:

Date of Last Refreshed on:

2015-05-02 15:23:12 

注册时间:

Date of Registration:

2009-06-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

聚焦超声和哈西奈德治疗外阴白色病变的全国多中心随机对照研究

Public title:

Comparison the efficacy and safety of focused ultrasound and halcinonide on white lesions of the vulva: a multi-center randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

聚焦超声和哈西奈德治疗外阴白色病变的全国多中心随机对照研究

Scientific title:

Comparison the efficacy and safety of focused ultrasound and halcinonide on white lesions of the vulva: a multi-center randomized controlled trial

研究课题代号(代码):

Study subject ID:

2008BAI57B06

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

朱兰 

研究负责人:

朱兰 

Applicant:

Lan Zhu 

Study leader:

Lan Zhu 

申请注册联系人电话:

Applicant telephone:

+86 0 13911714696

研究负责人电话:

Study leader's
telephone:

+86 0 13911714696

申请注册联系人传真 :

Applicant Fax:

+86 010 65124875

研究负责人传真:

Study leader's fax:

+86 010 65124875

申请注册联系人电子邮件:

Applicant E-mail:

zhu_julie@sina.com

研究负责人电子邮件:

Study leader's E-mail:

zhu_julie@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

www.pumch.ac.cn

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

www.pumch.ac.cn

申请注册联系人通讯地址:

北京市东城区帅府园1号北京协和医院妇产科

研究负责人通讯地址:

北京市东城区帅府园1号北京协和医院妇产科

Applicant address:

1 Shuaifuyuan, Dongcheng District, Beijing, China

Study leader's address:

1 Shuaifuyuan, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100730

研究负责人邮政编码:

Study leader's postcode:

100730

申请人所在单位:

北京协和医院

Applicant's institution:

Peking Union Medical College Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

S229

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中国医学科学院北京协和医院

Name of the ethic committee:

Peking Union Medical College Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2009-07-15 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京协和医院

Primary sponsor:

Peking Union Medical College Hospital

研究实施负责(组长)单位地址:

北京市东城区帅府园1号北京协和医院妇产科

Primary sponsor's address:

No.1, Shuaifu Garden,Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

国家科技部

具体地址:

北京市海淀区复兴路乙15号

Institution
hospital:

Ministry of Science and Technology

Address:

No.15B, Fuxing Road, Haidian District ,Beijing, China

经费或物资来源:

国家科技支撑项目

Source(s) of funding:

National Key Project

研究疾病:

外阴白色病变  

Target disease:

white lesions of the vulva

研究疾病代码:

N90.4

Target disease code:

N90.4

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

III期临床试验 

Study phase:

3

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

聚性焦超声治疗外阴白色病变的疗效和安全  

Objectives of Study:

To compare the efficacy and safety of focused ultrasound and halcinonide on white lesions of the vulva

药物成份或治疗方案详述:

哈西奈德(氯氟舒松、哈西缩松) 16α,17-[(1-甲基亚乙基)双(氧)]-11β-羟基-21-氯-9-氟孕甾-4-烯-3,20-二酮 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

① 一般的排除标准
? 禁用一般麻醉及局部麻醉或镇静剂的患者
? 严重心、脑、血管疾病及肝肾功能异常
? 生殖器官急性炎症
? 处于月经期、妊娠期及哺乳期的患者
② 外阴白色病变患者排除标准
- 外阴活检发现有外阴上皮内瘤样病变(VIN)的患者。
- 未控制的糖尿病
- 治疗前3个月进行过激光治疗、微波治疗等其他物理治疗。

Exclusion criteria:

1. Patients who were contradicted to general and local anesthesia or sedatives;
2. Patients with severe heart, brain or vascular disease or dysfunction in hepatic or kidney function;
3. Patients with acute infections in reproductive organ;
4. Patients in menstrual period, pregnancy or lactation;
5. Biopsy of Vulva indicated neoplastic epithelial disorders of vulva;
6. Patients with uncontrolled diabetes.

研究实施时间:

Study execute time:

From 2009-07-01 00:00:00 To 2011-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2009-07-01 00:00:00 To 2010-12-31 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

1020

Group:

1

Sample size:

干预措施:

聚焦超声

干预措施代码:

Intervention:

focused ultrasound

Intervention code:

组别:

2

样本量:

1020

Group:

2

Sample size:

干预措施:

哈西奈德乳膏

干预措施代码:

Intervention:

focused ultrasound

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京协和医院 

单位级别:

三甲医院 

Institution
hospital:

Peking Union Medical College Hospital

Level of the institution:

Tertiary Hospital

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重医 

单位级别:

三甲医院 

Institution
hospital:

Affiniated Hospitals of Chongqing Medical University

Level of the institution:

Tertiary hospital

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

华西第二医院 

单位级别:

三甲医院 

Institution
hospital:

West China the second hospital

Level of the institution:

Tertiary hospital

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属妇产科医院 

单位级别:

三甲医院 

Institution
hospital:

Gynecology and Obstetrics Hospital of Fudan University

Level of the institution:

Tertiary hospital

国家:

中国

省(直辖市):

贵州 

市(区县):

 

Country:

China

Province:

Guizhou

City:

单位(医院):

遵义医学院附属医院 

单位级别:

三甲医院 

Institution
hospital:

Zunyi medical school affiliated hospita

Level of the institution:

Tertiary hospital

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

第三军医大学附属西南 

单位级别:

三甲医院 

Institution
hospital:

The third military medical university in southwest subsidiar

Level of the institution:

Tertiary hospital

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

大坪医院 

单位级别:

三甲医院 

Institution
hospital:

DaPing hospitals

Level of the institution:

Tertiary hospital

测量指标:

Outcomes:

指标中文名:

疗效指数

指标类型:

主要指标

Outcome:

Effect index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

症状改善

指标类型:

次要指标

Outcome:

Symptoms improvements

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WHO生存质量测定

指标类型:

次要指标

Outcome:

Quality of Life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 70 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

计算机软件

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer Software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

北京协和医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Peking Union Medical College Hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

北京协和医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Peking Union Medical College Hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2009-06-22 00:00:00